You just read:

PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two Years with Nonsense Mutation Duchenne Muscular Dystrophy

News provided by

PTC Therapeutics, Inc.

Jul 09, 2018, 08:00 ET